A day in the life… page 4

Article

A day in the life

Previous page

Time to reflect

We usually finish morning clinic between 2 and 2.30 pm, and finally at this point we can relax. During this time we speak of our projects, work in progress, research programmes and participation in upcoming congresses.

One of the best things about our team is the friendliness and comradeship amongst us. It would be very difficult for somebody who has a different work ethic to mix with us. I therefore select our team members very carefully to make sure that their personality, as well as their skills, matches our team. I can honestly say that we are a nice team, and work is certainly more pleasant if the setting is relaxed.

No rest for the wicked

I begin my private practice in the afternoon, usually at 3.00 pm. My office is not in the hospital, but in an historic building very close to the city's cathedral. By the time I arrive, my secretary and my first patients are usually already there.

My practice is retina-oriented, but it is a general ophthalmology practice. My patient base is much smaller than that in the morning clinic, my working rhythm is far more relaxed and thankfully my patients are usually on time for their appointments.

My working day with patients finally comes to an end at around 7.00 pm but I usually stay in my office at least for another hour to read my e-mails, connect to the web, answer letters, and to organise the administrative aspects of my work.

After these tasks, my working day comes to an end and I can recharge my batteries ready for another day at the clinic to begin!

Previous page

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.